🔎 Trials Near Me

Akèy › Kasinom Selil Transizyonèl (Urotelyal) › Massachusetts › Boston

Etid klinik pou Kasinom Selil Transizyonèl (Urotelyal) nan Boston, MA

11 etid pou Kasinom Selil Transizyonèl (Urotelyal) ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Ap rekriteFaz 1
  • Exelixis Clinical Site #7, Boston
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Ap rekriteFaz 1
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Ap rekriteEtid obsèvasyon
  • Mass General Brigham, Boston
  • Brigham and Women's Hospital, Boston
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05874921

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Ap rekriteFaz 1/2
  • Tufts Medical Center, Boston
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Ap rekriteFaz 3
  • Massachusetts General Hospital, Boston
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Ap rekriteFaz 1
  • Dana Farber Cancer Institute, Boston
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Ap rekriteFaz 1
  • Dana-Farber Cancer Institute, Boston
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06966024

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Ap rekriteFaz 3
  • Research Site, Boston
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07720284

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Ap rekriteFaz 1
  • Dana Farber Cancer Institute, Boston
Laj 18 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT06451497

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Ap rekriteEtid obsèvasyon
  • Dana-Farber Cancer Institute, Boston
Laj 65 ak plis · Tout sèks · Mizajou Feb 17, 2026 · NCT06138561

Sacituzumab Govitecan Plus EV in Metastatic UC

Ap rekriteFaz 1/2
  • Dana Farber Cancer Institute, Boston
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT04724018

Etid Kasinom Selil Transizyonèl (Urotelyal) nan lòt vil

Lòt etid nan Boston

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.